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Cytokines signalling pathway genes are crucial factors of the genetic network underlying the 
pathogenesis of Immunoglobulin‑A vasculitis (IgAV), an inflammatory vascular condition. An 
influence of the interleukin (IL)33- IL1 receptor like (IL1RL)1 signalling pathway on the increased risk 
of several immune‑mediated diseases has been described. Accordingly, we assessed whether the 
IL33-IL1RL1 pathway represents a novel genetic risk factor for IgAV. Three tag polymorphisms within 
IL33 (rs3939286, rs7025417 and rs7044343) and three within IL1RL1 (rs2310173, rs13015714 and 
rs2058660), that also were previously associated with several inflammatory diseases, were genotyped 
in 380 Caucasian IgAV patients and 845 matched healthy controls. No genotypes or alleles differences 
were observed between IgAV patients and controls when IL33 and IL1RL1 variants were analysed 
independently. Likewise, no statistically significant differences were found in IL33 or IL1RL1 genotype 
and allele frequencies when IgAV patients were stratified according to the age at disease onset or to 
the presence/absence of gastrointestinal (GI) or renal manifestations. Similar results were disclosed 
when IL33 and IL1RL1 haplotypes were compared between IgAV patients and controls and between 
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IgAV patients stratified according to the clinical characteristics mentioned above. Our results suggest 
that the IL33-IL1RL1 signalling pathway does not contribute to the genetic network underlying IgAV.
Immunoglobulin-A vasculitis (IgAV), formerly called Henoch-Schönlein purpura (HSP), is an inflammatory 
small-sized blood vessel disease, more common in children and rarer but more serious in  adults1–3. The defin-
ing pathophysiologic feature of this vasculitis is the IgA1-predominant immune deposits in the vessel  walls1. 
Although IgAV usually involves the skin, joints and the gastrointestinal (GI)  tract4–8, nephritis is also common 
in affected patients and constitutes the most feared complication of this  vasculitis1–5. IgAV has a multifactorial 
aetiology in which genetics plays a relevant role in both the predisposition and clinical course of the  disease6,9,10. 
In this regard, outside the human leukocyte antigen region, cytokines signalling pathway genes constitute a key 
component of the genetic network underlying  IgAV6,11–14.
Interleukin (IL)-33 is a cytokine that belongs to the IL-1  family15. This molecule exerts its biological func-
tions by binding to its receptor, IL-1 receptor like 1 (IL-1RL1) (also known as suppression of tumorigenicity 2 
or ST2), a member of the Toll/IL-1 receptor  superfamily16. This binding leads to the activation of mast cells and 
Th2 lymphocytes and, consequently, to the production of chemokines, pro-inflammatory and Th2-associated 
cytokines, as well as increased serum immunoglobulin  levels15. In accordance with that, a pathogenic role of 
the IL-33 axis in autoimmunity has been  described17–19. In addition, several lines of evidence demonstrate that 
genetic variants located both in the IL33 and IL1RL1 genes are implicated in the increased risk of numerous 
immune-mediated  diseases20–28.
Taking into account all these considerations, this study aimed to determine, for the first time, the potential 
implication of the IL33-IL1RL1 signalling pathway in the pathogenesis of IgAV. For this purpose, we genotyped 
three tag genetic variants within IL33 and three tag polymorphisms within IL1RL1, which cover the major vari-
ability of these loci and that were previously associated with several inflammatory diseases, in the largest series 
of Caucasian IgAV patients ever assessed for genetic studies.
Patients and methods
Study population. A series of 380 unrelated Spanish patients of European ancestry who fulfilled Michel 
et al.  criteria29 and/or the American College of Rheumatology classification  criteria30 for IgAV-HSP and/or the 
2012 revised International Chapel Hill Consensus Conference  Nomenclature31 definition for IgAV were included 
in the present study. Centres involved in the recruitment of these patients included Hospital Universitario Mar-
qués de Valdecilla (Santander), Hospital Universitario San Cecilio (Granada), Hospital Universitario de Bellvitge 
(Barcelona), Hospital Universitario Lucus Augusti (Lugo), Hospital Universitario Central de Asturias (Oviedo), 
Hospital Universitario Severo Ochoa and Hospital Universitario de La Princesa (Madrid), Hospital Universitario 
Virgen del Rocío (Sevilla) and Hospital Universitario de Basurto (Bilbao). Information on the main clinical 
features of these patients is displayed in Table 1. For GI manifestations, bowel angina was considered present if 
there was diffuse abdominal pain that worsened after meals or bowel ischemia usually with bloody diarrhoea. GI 
bleeding was defined as the presence of melena, haematochezia, or a positive test for occult blood in the stool. 
Renal manifestations were defined to be present if at least one of the following findings was observed: haematu-
ria, proteinuria, or nephrotic syndrome at any time over the clinical course of the disease and/or renal sequelae 
(persistent renal involvement) at last follow-up.
In addition, a set of 845 sex and ethnically matched healthy controls without history of cutaneous vasculitis or 
any other autoimmune disease, constituted by blood donors from Hospital Universitario Marqués de Valdecilla 
(Santander) and National DNA Bank Repository (Salamanca), was also included in this study.
For experiments involving humans and the use of human blood samples, all the methods were carried out in 
accordance with the approved guidelines and regulations, according to the Declaration of Helsinki. All experi-
mental protocols were approved by the Ethics Committees of clinical research of Cantabria (for Hospital Uni-
versitario Marqués de Valdecilla, Santander), Ethics Committee of clinical research of Granada (for Hospital 
Universitario San Cecilio, Granada), Ethics Committee of clinical research of Barcelona (for Hospital Univer-
sitario de Bellvitge, Barcelona), Ethics Committee of clinical research of Galicia (for Hospital Universitario 
Lucus Augusti, Lugo), Ethics Committee of clinical research of Asturias (for Hospital Universitario Central de 
Asturias, Oviedo), Ethics Committee of clinical research of Madrid (for Hospital Universitario Severo Ochoa 
and Hospital Universitario de La Princesa, Madrid), Ethics Committee of clinical research of Sevilla (for Hos-
pital Universitario Virgen del Rocío, Sevilla) and Ethics Committee of clinical research of Euskadi (for Hospital 
Universitario de Basurto, Bilbao). Patients with IgAV and healthy controls signed an informed written consent 
before being included in the study.
Single nucleotide polymorphisms selection and genotyping methods. Three tag genetic variants 
within IL33 (rs3939286, rs7025417 and rs7044343) and three tag polymorphisms within IL1RL1 (rs2310173, 
rs13015714 and rs2058660) were selected in this study. Regarding IL33, rs3939286 is situated in an intergenic 
region close to IL33, whereas rs7025417 and rs7044343 are located in the promoter and in intron 5 of the gene, 
respectively. With respect to IL1RL1, both rs2310173 and r2058660 are placed close to IL1RL1, while rs13015714 
is downstream of the gene. Interestingly, these six polymorphisms map and tag both IL33 and IL1RL1 regions as 
previously  described20. In addition, the IL33 and IL1RL1 genetic variants selected in our study were previously 
associated with several immune-mediated  diseases20–28. In particular, IL33 rs3939286 was previously implicated 
in the development of subclinical atherosclerosis in patients with rheumatoid arthritis (RA)20 as well as in the 
pathogenesis of inflammatory bowel (IBD)  disease21 and  asthma22, whereas IL33 rs7025417 was previously asso-
ciated with coronary artery  disease23, and rs7044343 with  RA24. Regarding IL1RL1, a relevant role of rs2310173 
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in ankylosing  spondylitis25 and ulcerative  colitis26, as well as an association of rs13015714 with celiac disease 27 
and  IBD21, and an influence of rs2058660 on the development of Crohn’s  disease28 were previously reported.
Genomic deoxyribonucleic acid (DNA) from all the individuals included in the study was extracted from 
peripheral blood using standard procedures.
Patients with IgAV and healthy controls were genotyped for the six polymorphisms mentioned above 
using predesigned TaqMan 5′ single-nucleotide polymorphism genotyping assays (C___2762168_10 for 
rs3939286, C__31940410_20 for rs7025417, C__29340326_10 for rs7044343, C___2676437_10 for rs2310173, 
C__31439507_10 for rs13015714 and C__11487892_10 for rs2058660).
Genotyping was performed in a QuantStudioTM 7 Flex Real-Time polymerase chain reaction system, accord-
ing to the conditions recommended by the manufacturer (Applied Biosystems, Foster City, CA, USA).
Negative controls and duplicate samples were included to check the accuracy of the genotyping.
Statistical analyses. Genotype data were checked for deviation from Hardy–Weinberg equilibrium 
(HWE).
Differences in IL33 and IL1RL1 frequencies were evaluated between patients with IgAV and healthy controls 
and between patients with IgAV stratified according to specific clinical characteristics of the disease (age at 
disease onset or presence/absence of GI or renal manifestations).
First, each IL33 and IL1RL1 polymorphism was analysed independently. Both genotype and allele frequencies 
were calculated and compared between the groups mentioned above by chi-square test. Strength of association 
was estimated using odds ratios (OR) and 95% confidence intervals (CI).
Then, allelic combinations (haplotypes) of both IL33 and IL1RL1 polymorphisms were carried out. Haplo-
type frequencies were calculated by the Haploview v4.2 software (http:// broad. mit. edu/ mpg/ haplo view) and 
then compared between the groups mentioned above by chi-square test. Strength of association was estimated 
by OR and 95% CI.
P-values were two-tailed and those lower than 0.05 were considered as statistically significant. All analyses 
were performed with the STATA statistical software 12/SE (Stata Corp., College Station, TX, USA).
Results
Genotyping quality control. IL33 rs3939286, IL33 rs7025417, IL33 rs7044343, IL1RL1 rs2310173, IL1RL1 
rs13015714 and IL1RL1 rs2058660 were in HWE.
The genotyping success rate for each polymorphism evaluated in this study was 99.9% for IL33 rs3939286, 
99.4% for IL33 rs7025417, 99.8% for IL33 rs7044343, 100% for IL1RL1 rs2310173, 99.6% for IL1RL1 rs13015714 
and 99.8% for IL1RL1 rs2058660.
Genotype and allele frequencies of each IL33 and IL1RL1 polymorphism were similar to that reported for 
populations of European origin in the 1000 Genomes Project (http:// www. inter natio nalge nome. org/).
Differences in IL33 and IL1RL1 genotype and allele frequencies between patients with IgAV 
and healthy controls. In a first step, we compared genotype and allele frequencies of each IL33 and IL1RL1 
variant assessed independently between patients with IgAV and healthy controls.
As shown in Table 2, similar genotype and allele IL33 and IL1RL1 frequencies were observed in patients with 
IgAV when compared to healthy controls (Table 2).
Differences in IL33 and IL1RL1 genotype and allele frequencies between patients with IgAV 
stratified according to specific clinical characteristics of the disease. Then, potential differences 
Table 1.  Main clinical features of the 380 patients with IgAV included in the study. IgAV: IgA vasculitis; IQR: 
interquartile range; GI: gastrointestinal. *At any time over the clinical course of the disease. **At last follow-up.
% (n)
Children (age ≤ 20 years)/ adults (age > 20 years) (n) 294/86
Percentage of females 47.9
Age at disease onset (years, median [IQR]) 7(5–19)
Duration of follow-up (years, median [IQR]) 1 (1–3)
Palpable purpura and/or maculopapular rash 100 (380)
Arthralgia and/or arthritis 52.9 (201)
GI manifestations (if “a” and/or “b”) 53.2 (202)
 (a) Bowel angina 50.5 (192)
 (b) GI bleeding 16.3 (62)
Renal manifestations (if any of the following characteristics) 36.1 (137)
 (a) Haematuria* 34.5 (131)
 (b) Proteinuria* 32.9 (125)
 (c) Nephrotic syndrome* 5.5 (21)
 (d) Renal sequelae (persistent renal involvement) ** 6.6 (25)
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in the genotype and allele frequencies of each IL33 and IL1RL1 genetic variant were evaluated between patients 
with IgAV stratified according to specific clinical characteristics of the disease.
Given that IgAV is often a benign and self-limited pathology in children and a more severe condition in adults, 
we assessed if potential differences in IL33 and IL1RL1 could exist in IgAV patients stratified according to the 
age at disease onset. With this respect, and as shown in Table 3, similar genotype and allele IL33 and IL1RL1 
frequencies were disclosed when children (age ≤ 20 years) were compared to adults (age > 20 years) (Table 3).
In addition, we compared genotype and allele frequencies of IL33 and IL1RL1 in patients with IgAV strati-
fied according to the presence/absence of GI or renal manifestations. Accordingly, similar genotype and allele 
IL33 and IL1RL1 frequencies were disclosed when patients with IgAV who developed GI manifestations were 
compared to those who did not exhibit these complications (Table 3). This was also the case when patients with 
IgAV were stratified according to the presence/absence of renal manifestations (Table 3).
Haplotype analyses of IL33 and IL1RL1. In a further step, we also examined whether haplotype fre-
quencies of both IL33 and IL1RL1 differed between patients with IgAV and healthy controls as well as between 
patients with IgAV stratified according to the specific clinical characteristics of the disease mentioned above.
The haplotype analysis did not yield additional information since IL33 and IL1RL1 haplotypes frequencies 
were similar in patients with IgAV when compared to healthy controls (Table 4). This was also the case when 
patients with IgAV were stratified according to the age at disease onset and the presence/absence of GI or renal 
manifestations (Supplementary Tables S1–S3 online).
Discussion
Several pieces of evidence clearly indicate that a common genetic background may underlie different inflamma-
tory  diseases32,33. In this regard, the IL33-IL1RL1 signalling pathway is described as a shared genetic risk factor 
for numerous immune-related  diseases20–28.
Based on these considerations, in this study we aimed to determine whether the IL33-IL1RL1 signalling 
pathway is also implicated in the pathogenesis of IgAV, a small-vessel vasculitis in which cytokines signalling 
pathway genes are considered as an essential component in its  etiology6,11–14. For that purpose, six polymorphisms 
within the IL33-IL1RL1 signalling pathway, which cover most of the variability of both IL33 and IL1RL1 regions 
and that were previously related to numerous immune-mediated  diaseases20–28, were evaluated in the largest 
series of Caucasian patients with IgAV ever assessed for genetic studies. Our results showed no influence of the 
IL33-IL1RL1 signalling pathway on the susceptibility to IgAV when we studied each of the polymorphisms sepa-
rately. Moreover, when we analysed IL33 genetic variants as well as IL1RL1 polymorphisms together conforming 
haplotypes, our results revealed a lack of association between the IL33-IL1RL1 signalling pathway and IgAV 
susceptibility. Furthermore, no specific association of IL33 and IL1RL1 polymorphisms (assessed independently 
or combined conforming haplotypes) with clinical features of IgAV was observed in our study, indicating that 
this pathway does not represent a risk factor for the severity of the disease.
Data on the potential effect of the IL33-IL1RL1 signalling pathway on vasculitis were scarce so far. A study 
performed in Caucasians evaluated the role of this pathway in the susceptibility to giant cell arteritis (GCA)34, 
another primary systemic vasculitis that involves large and middle-sized blood  vessels31,35. In keeping with our 
results, no influence of IL33 rs3939286, IL33 rs7044343, IL1RL1 rs2310173, IL1RL1 rs13015714 and IL1RL1 
rs2058660 on GCA was  detected34. By contrast, a consistent association between IL33 rs7025417 and GCA was 
Table 2.  Genotype and allele frequencies of IL33 and IL1RL1 genes in patients with IgAV and healthy 
controls. IgAV: IgA vasculitis; SNP: single nucleotide polymorphism. No statistically significant differences in 
the IL33 and IL1RL1 genotype and allele frequencies were disclosed when patients with IgAV were compared 
to healthy controls (p ≥ 0.05 in all the cases).
Change Genotypes, % (n) Alleles, % (n)
Locus SNP 1/2 Samples set 1/1 1/2 2/2 1 2
IL33 rs3939286 C/T IgAV patients 49.1 (186) 40.9 (155) 10.0 (38) 69.5 (527) 30.5 (231)
Healthy controls 49.0 (414) 41.4 (350) 9.6 (81) 69.7 (1178) 30.3 (512)
IL33 rs7025417 T/C IgAV patients 68.1 (254) 29.5 (110) 2.4 (9) 82.8 (618) 17.2 (128)
Healthy controls 70.8 (598) 25.9 (219) 3.3 (28) 83.7 (1415) 16.3 (275)
IL33 rs7044343 T/C IgAV patients 42.3 (160) 42.1 (159) 15.6 (59) 63.4 (479) 36.6 (277)
Healthy controls 44.5 (376) 43.9 (371) 11.6 (98) 66.4 (1123) 33.6 (567)
IL1RL1 rs2310173 G/T IgAV patients 29.2 (111) 46.1 (175) 24.7 (94) 52.2 (397) 47.8 (363)
Healthy controls 30.2 (255) 46.7 (395) 23.1 (195) 53.6 (905) 46.4 (785)
IL1RL1 rs13015714 T/G IgAV patients 56.3 (211) 39.5 (148) 4.3 (16) 76.0 (570) 24.0 (180)
Healthy controls 57.2 (483) 37.2 (314) 5.7 (48) 75.7 (1280) 24.3 (410)
IL1RL1 rs2058660 A/G IgAV patients 56.9 (215) 38.6 (146) 4.5 (17) 76.2 (576) 23.8 (180)
Healthy controls 56.7 (479) 37.5 (317) 5.8 (49) 75.4 (1275) 24.6 (415)
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found, pointing out this polymorphism as a novel genetic risk factor for GCA  susceptibility34. In addition, the 
potential role of an IL33 polymorphism (rs1342326) in the pathogenesis of Behçet’s disease, a condition affecting 
blood vessels of all sizes and  types31, was assessed in  Iranians36. With this respect, an effect of this genetic variant 
in the susceptibility to this disease was  disclosed36.
The results derived from our study are of potential clinical relevance. Vasculitides comprises a heterogeneous 
group of autoimmune diseases that often have overlapping clinical and pathological  manifestations37. Although 
their complex aetiology is far from being completely understood, differences among them in molecular terms 
have been  postulated38. Our data support this hypothesis since no implication of the IL33-IL1RL1 signalling 
pathway in the pathogenesis of IgAV in Caucasians was disclosed, unlike GCA 34.
Table 3.  Genotype and allele frequencies of IL33 and IL1RL1 genes in patients with IgAV stratified according 
to clinical characteristics of the disease. IgAV: IgA vasculitis; GI: gastrointestinal. No statistically significant 
differences in the IL33 and IL1RL1 genotype and allele frequencies were disclosed between patients with IgAV 
stratified according to the age at disease onset, the presence/absence of GI or renal manifestations (p ≥ 0.05 in 
all the cases).
Polymorphism
Children (Age ≤ 20 years) GI manifestations Renal manifestations
Yes (n = 294) No (n = 86) Yes (n = 202) No (n = 178) Yes (n = 137) No (n = 243)
IL33 rs3939286
CC 47.8 (140) 53.5 (46) 47.3 (95) 51.1 (91) 48.5 (66) 49.4 (120)
CT 42.0 (123) 37.2 (32) 42.3 (85) 39.3 (70) 39.7 (54) 41.6 (101)
TT 10.2 (30) 9.3 (8) 10.4 (21) 9.6 (17) 11.8 (16) 9.1 (22)
C 68.8 (403) 72.1 (124) 68.4 (275) 70.8 (252) 68.4 (186) 70.2 (341)
T 31.2 (183) 27.9 (48) 31.6 (127) 29.2 (104) 31.6 (86) 29.8 (145)
IL33 rs7025417
TT 66.6 (191) 73.3 (63) 68.2 (135) 68.0 (119) 69.9 (93) 67.1 (161)
TC 31.0 (89) 24.4 (21) 28.8 (57) 30.3 (53) 27.1 (36) 30.8 (74)
CC 2.4 (7) 2.3 (2) 3.0 (6) 1.7 (3) 3.0 (4) 2.1 (5)
T 82.1 (471) 85.5 (147) 82.6 (327) 83.1 (291) 83.5 (222) 82.5 (396)
C 17.9 (103) 14.5 (25) 17.4 (69) 16.9 (59) 16.5 (44) 17.5 (84)
IL33 rs7044343
TT 44.2 (129) 36.0 (31) 43.9 (88) 40.7 (72) 44.5 (61) 41.1 (99)
TC 39.4 (115) 51.2 (44) 39.8 (80) 44.6 (79) 39.4 (54) 43.6 (105)
CC 16.4 (48) 12.8 (11) 16.4 (33) 14.7 (26) 16.1 (22) 15.4 (37)
T 63.9 (373) 61.6 (106) 63.7 (256) 63.0 (223) 64.2 (176) 62.9 (303)
C 36.1 (211) 38.4 (66) 36.3 (146) 37.0 (131) 35.8 (98) 37.1 (179)
IL1RL1 rs2310173
GG 29.6 (87) 27.9 (24) 30.2 (61) 28.1 (50) 32.1 (44) 27.6 (67)
GT 45.2 (133) 48.8 (42) 45.0 (91) 47.2 (84) 43.1 (59) 47.7 (116)
TT 25.2 (74) 23.3 (20) 24.8 (50) 24.7 (44) 24.8 (34) 24.7 (60)
G 52.2 (307) 52.3 (90) 52.7 (213) 51.7 (184) 53.6 (147) 51.4 (250)
T 47.8 (281) 47.7 (82) 47.3 (191) 48.3 (172) 46.4 (127) 48.6 (236)
IL1RL1 rs13015714
TT 55.5 (161) 58.8 (50) 57.3 (114) 55.1 (97) 61.8 (84) 53.1 (127)
TG 40.0 (116) 37.6 (32) 40.2 (80) 38.6 (68) 33.8 (46) 42.7 (102)
GG 4.5 (13) 3.5 (3) 2.5 (5) 6.3 (11) 4.4 (6) 4.2 (10)
T 75.5 (438) 77.6 (132) 77.4 (308) 74.4 (262) 78.7 (214) 74.5 (356)
G 24.5 (142) 22.4 (38) 22.6 (90) 25.6 (90) 21.3 (58) 25.5 (122)
IL1RL1 rs2058660
AA 56.3 (165) 58.8 (50) 57.9 (117) 55.7 (98) 62.2 (84) 53.9 (131)
AG 39.2 (115) 36.5 (31) 39.1 (79) 38.1 (67) 31.9 (43) 42.4 (103)
GG 4.4 (13) 4.7 (4) 3.0 (6) 6.3 (11) 5.9 (8) 3.7 (9)
A 75.9 (445) 77.1 (131) 77.5 (313) 74.7 (263) 78.1 (211) 75.1 (365)
G 24.1 (141) 22.9 (39) 22.5 (91) 25.3 (89) 21.9 (59) 24.9 (121)
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In summary, based on a large series of Caucasian patients, our results suggest that the IL33-IL1RL1 signalling 
pathway does not contribute to the genetic network underlying IgAV.
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